months or shorter) placebo-controlled studies. Improvements were shown in patient-reported outcomes, composite response criteria, and spine and sacroiliac inflammation on magnetic resonance imaging http://onlin elibr ary.wiley.com/doi/10.1002/ art.41042/ abstract In adults with active AS despite treatment with NSAIDs, we strongly recommend treatment with secukinumab or ixekizumab over no treatment with secukinumab or ixekizumab (new, PICO 58). In adults with active AS despite treatment with